Abstract

Paracrine activation of cells contained in the tumor microenvironment promotes tumor progression and metastasis. In breast cancer, malignant cells recruit and educate macrophages into a M2 tumor-promoting phenotype that supports the metastatic spread of cancer cells. Here, we show that miR-149 functions as a metastasis-suppressing microRNA in breast cancer cells by limiting colony-stimulating factor-1 (CSF1)-dependent recruitment and M2 polarization of macrophages. In lymph node-positive, triple-negative breast cancer (TNBC) tissues, low miR-149 expression correlated with macrophage infiltration and reduced patient survival. By directly targeting CSF1, miR-149 expression in TNBC cell lines (MDA-MB-231 and BT-549) inhibited the recruitment of human monocytic THP-1 cells and primary human macrophages. Furthermore, in macrophages cocultured with MDA-MB-231 cells expressing miR-149, epidermal growth factor (EGF) and amphiregulin expression levels were strongly reduced, resulting in reduced EGF receptor activation in the cancer cells. In vivo, lung metastases developing from orthotopic MDA-MB-231 tumors were reduced by 75% by miR-149 expression, and this was associated with impaired M2 macrophage infiltration of the primary tumors. These data suggest that miR-149 downregulation functionally contributes to breast tumor progression by recruiting macrophages to the tumor and facilitating CSF1 and EGF receptor cross-talk between cancer cells and macrophages. SIGNIFICANCE: These findings contribute to the understanding of tumor-stroma interactions by showing that miR-149 downregulation in TNBC enhances reciprocal growth factor signaling between macrophages and cancer cells, which promotes tumor progression and metastasis. GRAPHICAL ABSTRACT: http://cancerres.aacrjournals.org/content/canres/80/6/1330/F1.large.jpg.

Highlights

  • In order to identify if miR-149 expression could serve as a prognostic marker in Triple-negative breast cancer (TNBC), our collaborators Melanie Boerries and Hauke Busch, analyzed the overall survival of 987 breast cancer patients f rom the cancer genome atlas with respect to lymph node metastasis, triplenegative breast cancer (TNBC) status and expression strength of miR-149 (Fig. 4)

  • The expression of only f ive of these genes (CSF1, VAV1, semaphorin 4D (SEMA4D), epidermal growth factor receptor (EGFR) and PRTPO) was significantly anti-correlated with that of miR-149 in the lymph node-positive TNBC tissue samples

  • In comparison to the control, lung micrometastasis f ormation, as determined by vimentin staining, was significantly reduced in mice harboring primary tumors expressing miR-149 (Figure 220A, B). These findings provide evidence that miR-149 f unctions as a metastasis-suppressing miRNA in breast cancer cells by limiting colony stimulatory f actor 1 (CSF1)-dependent recruitment and M2 polarization of macrophages

Read more

Summary

Introduction

1.1 Breast cancerCancer is a generic term that ref ers to over 200 dif ferent disease entities that can affect any part of the body. In 2018, the breast cancer incidence was estimated at 2.1 million new cases, representing 24.2% of all cancers in women; 626,679 women with breast cancer died (Bray et al 2018). Breast cancer has a broad clinical and molecular heterogeneity and several classifications have been developed to group tumors . Clinical practice f requently uses a surrogate classification of five subtypes based on histology and immunohistochemistry expression of key proteins: estrogen receptor (ER), progesterone receptor (PR), human epidermal growth f actor receptor 2 (HER2) and the proliferation marker Ki67 (Harbeck et al 2019); giving rise to Luminal A-like (Strongly ER+ and PR+; HER2–; low Ki67), Luminal B-like HER2– (ER+ but ER and PR expression lower than in luminal A-like; high Ki67), HER2-enriched (ER–, PR–, HER2+; high Ki67), Luminal B-like HER2+ (ER+ but lower ER and PR expression than luminal A-like; HER2+; high Ki67) and triple-negative (ER–, PR–, HER2–; high Ki67) breast cancer

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call